Low-dose alemtuzumab (Campath®) in myeloablative allogeneic stem cell transplantation for CD52-positive malignancies: Decreased incidence of acute graft-versus-host-disease with unique pharmacokinetics

Bone Marrow Transplantation

Volumn 33, Issue 8, 2004, Pages 833-837

  Khouri, I F ^a   Albitar, M ^a   Saliba, R M ^a   Ippoliti, C ^a   Ma, Y C ^a   Keating, M J ^a   Champlin, R E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Alemtuzumab; Allogeneic stem cell transplantation

Indexed keywords

ALEMTUZUMAB; ANTIINFECTIVE AGENT; CD52 ANTIGEN; CYCLOPHOSPHAMIDE; DIPHENHYDRAMINE; FLUCONAZOLE; FOSCARNET; HYDROCORTISONE; IMMUNOGLOBULIN; LEVOFLOXACIN; METHOTREXATE; MYELOABLATIVE AGENT; PARACETAMOL; TACROLIMUS; VALGANCICLOVIR;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BLOOD SAMPLING; CANCER SURVIVAL; CHIMERA; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HUMAN; INCIDENCE; LOW DRUG DOSE; MALE; NEUTROPHIL; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTE COUNT; WHOLE BODY RADIATION;

ACUTE DISEASE; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIGENS, CD; ANTIGENS, NEOPLASM; FEMALE; GLYCOPROTEINS; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, B-CELL, ACUTE; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE; MIDDLE AGED; TRANSPLANTATION, HOMOLOGOUS;

EID: 1942474338     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704435     Document Type: Article

References (25)

1. Ginaldi L, De Martinis M, Matutes E et al. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. Leuk Res 1998; 22: 185-191.
2. Gilleece MH, Dexter TM. Effect of Campath-1H antibody on human hematopoietic progenitors in vitro. Blood 1993; 82: 807-812.
3. Hale G. The CD52 antigen and development of the Campath antibodies. Cytotherapy 2001; 3: 137-143.
4. Keating MJ, Flinn I, Jain V et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002; 99: 3554-3561.
5. Osterborg A, Dyer MJ, Bunjes D et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol 1997; 15: 1567-1574.
6. Osterborg A, Fassas AS, Anagnostopoulos A et al. Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia. Br J Haematol 1996; 93: 151-153.
7. Lundin J, Kimby E, Bjorkholm M et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia. Blood 2002; 100: 768-773.
8. Pawson R, Dyer MJ, Barge R et al. Treatment of T-cell prolymphocytic leukemia with human CD52 antibody. J Clin Oncol 1997; 15: 2667-2672.
9. Keating MJ, Cazin B, Coutre S el al. Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. J Clin Oncol 2002; 20: 205-213.
10. Dearden C, Matutes E, Cazin B et al. High remission rate in T-cell prolymphocytic leukemia with Campath-1H. Blood 2001; 98: 1721-1726.
11. Dyer MSJ, Hale G, Marcus R Waldmann H. Remission induction in patients with lymphoid malignancies using unconjugated Campath-1H monoclonal antibodies. Leuk Lymphoma 1990; 2: 179-193.
12. Hale G, Jacobs P, Wood L et al. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells. Bone Marrow Transplant 2000; 26: 69-76.
13. Hale G, Waldmann H. Recent results using CAMPATH-1 antibodies to control GVHD and graft rejection. Bone Marrow Transplant 1996; 17: 305-308.
14. Hale G, Cobbold S, Waldmann H. T cell depletion with CAMPATH-1 in allogeneic bone marrow transplantation. Transplantation 1998; 45: 753-759.
15. Clarke E, Potter MN, Hale G et al. Double T cell depletion of bone marrow using sequential positive and negative cell immunoaffinity or CD34+ cell selection followed by Campath-1M; effect on CD34 + cells and progenitor cell recoveries. Bone Marrow Transplant 1998; 22: 117-124.
16. Perez-Simon JA, Kottaridis PD, Martino R et al. Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood 2002; 100: 3121-3127.
17. Chakraverty R, Peggs K, Chopra R et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood 2002; 99: 1071-1078.
18. Cull GM, Haynes AP, Byrne JL et al. Preliminary experience of allogeneic stem cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH conditioning: an effective regimen with low procedure-related toxicity. Br J Haematol 2000; 108: 754-760.
19. Kottaridis PD, Milligan DW, Chopra R et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood 2000; 96: 2419-2425.
20. Manshouri T, Keating M, Giles FS et al. Measuring Campath-1H: validation of a sensitive and simple enzyme-linked immunosorbent assay. Blood 2002; 100: 360b.
21. Morris EC, Rebello P, Thomson KJ et al. Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantation: relevance for early adoptive immunotherapy and infectious complication. Blood 2003; 102: 404-406.
22. Morris E, Thomson K, Craddock C et al. Long-term follow-up of an alemtuzumab (Campath-1h) containing reduced intensity allogeneic transplant regimen for non-Hodgkin's lymphoma (NHL). Blood 2002; 100: 40a.
23. Przepiorka D, Cortes J, Folloder J et al. Allogeneic transplantation for adult lymphocytic leukemia. Blood 1998; 10: 354b.
24. Klangsinsirikul P, Carter GI, Byrne JL et al. Campath-1G causes rapid depletion of circulating host dendritic cells (DCs) before allogeneic transplantation but does not delay donor DC reconstitution. Blood 2002; 99: 2586-2591.
25. Ratzinger G, Reagan JL, Heller G et al. Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation. Blood 2003; 101: 1422-1429.